From Random Cleavage to Precision Correction: CRISPR Gene Scissors Open New Horizons for Customized Genetic Disease Treatment
Background
CRISPR gene-editing technology, derived from the adaptive immune defense mechanism of bacteria, has fundamentally changed the paradigm of genome editing in life sciences. The first-generation zinc finger nucleases (ZFNs) and second-generation TALENs required complex protein engineering design processes, resulting in high production costs and significant time consumption. Why did early academia remain stuck with these cumbersome tools? This was due to structural limitations that required the target recognition sites and cleavage enzymes to be synthesized individually as recombinant proteins.
In contrast, third-generation CRISPR-Cas9 demonstrated the ability to flexibly target specific deoxyribonucleic acid (DNA) sequences through the binding of a single guide RNA (sgRNA) and Cas9 protein, significantly lowering the barrier to entry for research. However, early technologies revealed clear limitations for direct use as clinical therapeutics. The most serious problem was the risk of off-target cleavage, where unintended sites similar to the target sequence are cut. This is because the Non-Homologous End Joining (NHEJ) pathway, which joins the cleavage sites, causes random base insertions and deletions, leading to genomic instability such as chromosomal translocation. Unpredictable editing outcomes and cytotoxicity have been fatal obstacles in the development of systemically administered new drugs.
Key Discoveries
This review paper deeply illuminates the trajectory of technological advancement that CRISPR, originating from prokaryotic immune systems, has undergone to leap into a core platform for precision medicine. It highlights three axes of development pursued by academia and industry to enhance editing accuracy and safety.
The first axis is the improvement of enzyme specificity achieved through protein engineering. High-fidelity Cas9 (HiFi Cas9) variants were developed by redesigning the non-specific binding sites of wild-type SpCas9. This achieved a reduction in off-target cleavage frequency by dozens of times or more compared to existing methods, while maintaining on-target cleavage activity. This result was achieved by lowering non-specific binding energy to induce cleavage only under conditions of perfect complementarity with the target sequence.
The second axis is the establishment of a new paradigm of precision editors that exclude DNA double-strand breaks (DSBs). The emergence of Base Editors (BE), which chemically alter specific single bases, and Prime Editors (PE), which combine reverse transcriptase. BE boasts precision by linking cytosine or adenine deaminase to an inactivated Cas9 to substitute C with T, or A with G. PE uses prime editing guide RNA (pegRNA) as a template to induce insertion, deletion, or substitution of desired sequences without double-strand breaks, fundamentally blocking the risk of genome damage.
The third axis, the evolution of in vivo delivery vehicles, is also noteworthy. Early Adeno-Associated Virus (AAV) vectors raised concerns regarding immune responses, random insertion into the genome, and long-term toxicity due to continuous expression. Researchers have paved the way for safety improvements by focusing on transient expression systems utilizing Lipid Nanoparticles (LNP) and Ribonucleoprotein (RNP) complexes.
Significance and Outlook
The evolution of CRISPR technology, which maximizes precision, offers practical therapeutic hope to patients with genetic diseases. The era of commercialization has begun with the product approval of Casgevy, a treatment for sickle cell anemia.
Will laboratory success directly lead to the treatment of all patients with incurable diseases? Significant technical and institutional challenges still hinder commercialization and indication expansion. Unlike ex vivo therapies that edit cells outside the body, there is high variability in delivery efficiency when injecting drugs directly in vivo to organs other than the liver.
The ultra-high drug prices, which can reach billions of won per patient, also constitute an economic barrier to patient access. This is a challenge to overcome for patient-specific therapies to become established as standard treatments. It is also urgent to establish global regulatory guidelines in response to concerns over germline editing and to build long-term safety tracking systems after treatment. This is the moment CRISPR, having demonstrated target specificity, safety, and predictability, leaps forward to become the central axis of future precision medicine.
Since its introduction as a genome-editing tool, CRISPR-based technology has undergone rapid refinement, with precision emerging as a central focus of development. Early CRISPR-Cas9 systems demonstrated unprecedented ease and efficiency in targeting specific DNA sequences, but concerns over off-target effects and variable editing outcomes limited their broader application. This review outlines the progression of CRISPR from its discovery in prokaryotes to its application as a versatile tool in precision medicine, where it supports targeted therapies for genetic disorders in various ways. Although technical challenges, including off-target editing and delivery inefficiencies, persist alongside ethical considerations of accessibility and long-term consequences, CRISPR's ongoing refinements and innovations reflect a clear trajectory toward greater specificity, safety, and predictability, positioning CRISPR as an increasingly precise platform for both fundamental research and therapeutic use.
Precision genome editing technology is reshaping therapeutic design strategies in biopharmaceutical R&D, shifting from inducing gene deletions to restoring causative mutations. While early therapeutics were limited to simply disrupting specific genes, precise targeted therapies that revert single-nucleotide variants causing diseases back to their normal sequences are becoming a reality.
A representative application scenario is the entry into clinical trials of LNP-based therapeutics for direct in vivo administration. Trials are underway to inhibit the production of proteins causing transthyretin amyloidosis (ATTR) or familial hypercholesterolemia via a single intravenous injection by loading base editor messenger RNA (mRNA) and guide RNA into liver-specific LNPs.
The advent of Prime Editing enables simultaneous customized genome insertion and correction, contributing to a significant increase in the production yield of allogeneic CAR-T cell therapies. By mass-editing immune cells from healthy donors without the risk of tumorigenesis associated with off-target cleavage, it is expected to accelerate the commercialization of next-generation anticancer cell therapies in an 'off-the-shelf' format.